Calidi Biotherapeutics (CLDI) Appoints George Peoples to its Board

Calidi Biotherapeutics, Inc. (NYSE American: CLDI), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today announced the appointment of Dr. George E. Peoples, MD, FACS, to the company’s Board of Directors, effective July 1, 2024.

“Dr. Peoples is a highly esteemed figure in the field of cancer immunotherapy, bringing decades of experience in cancer vaccine development and clinical research to our Board,” said Allan Camaisa, CEO and Chairman of the Board of Calidi Biotherapeutics. “Dr. Peoples’ pioneering work in cancer immunotherapy and his extensive experience in both clinical and military settings will be invaluable as we advance our portfolio of cancer immunotherapies into later-stage clinical trials.”

Dr. Peoples is the Founder and Director of the Cancer Vaccine Development Program (CVDP), with over 20 years of experience in discovering, developing, and clinically testing cancer vaccines, four of which have been licensed for commercial development. He also founded LumaBridge (formerly Cancer Insight), an oncology-focused Contract Research Organization (CRO) and development partner currently engaged with over 25 pre-clinical and clinical trial sponsors.

In addition to his roles at CVDP and LumaBridge, Dr. Peoples serves as a Professor of Surgery at the Uniformed Services University of the Health Sciences (USUHS) and an adjunct Professor of Surgical Oncology at MD Anderson Cancer Center. He has held significant positions such as Chair of the Cancer Care Program at San Antonio Military Medical Center and Military Director of the United States Military Cancer Institute. Dr. Peoples is a graduate of the United States Military Academy at West Point and the Johns Hopkins School of Medicine, and he completed his surgical training at Harvard’s Brigham and Women’s Hospital and a surgical oncology fellowship at MD Anderson Cancer Center. He has authored over 350 peer-reviewed manuscripts, abstracts, and book chapters.

“Calidi Biotherapeutics has made remarkable strides in the development of allogeneic stem cell therapies and oncolytic virus delivery systems,” said Dr. Peoples. “I am excited to join the Board and contribute to the company’s innovative approach to cancer treatment. I look forward to working with the Calidi team to advance these promising therapies through clinical development and towards commercialization.”

You May Also Be Interested In

• Bausch + Lomb names Appio as chairman, reshapes board committees
• SU Group signs MoU to expand security training across Greater China
• D-Wave receives CAD $300K from Canada's NRC for quantum software